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Abstract
Cancer is a complex genetic and epigenetic-based disease that has developed 
a multitude of mechanisms in evading cell death. Deregulation of apoptosis and 
autophagy are commonly encountered during the development of human tumors. 
Histone deacetylase inhibitors (HDACi) have been employed to reverse epigeneti-
cally deregulated gene expression caused by aberrant post-translational protein 
modifications. These interfere with histone acetyltransferase- and deacetylase-
mediated acetylation of histone and non-histone proteins, and thereby exert a wide 
array of HDACi-stimulated cytotoxic effects. Key determinants of HDACi lethality 
that interfere with cellular growth in a multitude of tumor cells are apoptosis and 
autophagy. Currently, the factors that determine the mode of HDACi-elicited cell 
death are mostly unclear however. Experimental evidence of the last decade con-
vincingly reports that the frequently mutated tumor suppressor protein p53 can act 
either as an activator or as an inhibitor of autophagy depending on its subcellular 
localization, and linked to its mode of action. Consistently, we recently described 
p53 as a regulatory switch that governs if histone deacetylase inhibitor-adminis-
tered uterine sarcoma cells undergo autophagy or apoptosis. By highlighting this 
novel finding, we summarize in this chapter the role of p53-mediated signaling dur-
ing the activation of the autophagic pathway in tumor cells in response to HDACi.
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1. Introduction
Evading cell death has been defined as a cornerstone of cancer development [1, 2]. 
Exploring the pathogenetic mechanisms that determine different cell death modes 
therefore facilitated the avenue for increased specifically directed interference with 
these molecular pathways. Morphologically, apoptosis, autophagy, and necrosis could 
be distinguished as major categories of programmed cell death very early that either 
act mutually exclusive or in combination involving cross talk for the elimination of 
tumor cells. While apoptosis and necrosis lead to inevitable cellular demise, autoph-
agy can have either a cytotoxic or a cytoprotective function [3]. Basal autophagy in 
normal eukaryotic cells provide a possibility to save energy and reuse damaged or 
aged macromolecules or organelles by redirecting them toward lysosomal degrada-
tion via so-called autophagosomes and can be triggered by nutrient-starving condi-
tions [4, 5]. Thus, in early phases of tumorigenesis, autophagy obviously presumes a 
cytoprotective or pro-survival role by suppressing necrosis and inflammation with 
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concomitant disruption of necrotic and apoptotic cell death induction [6, 7]. In later 
stages of irreversible tumor development however, autophagy may promote cell death 
by largely non-elucidated mechanisms that expedite the “self-degradation” program 
[8]. Disruption of autophagy in the latter case, which was recently enforced as novel 
strategy in chemotherapeutic cancer treatment, will advance the survival of tumor 
cells. This insight stresses the significance to confirm the context-reliant function of 
autophagy before initiating cancer therapy involving autophagic intervention [9, 10].
2. The molecular mechanism of autophagy
During macro-autophagy the formation of autophagosomes, representing double 
enveloped vesicles that enable the engulfment of targeted long-lived molecules and 
other cellular complexes from the remaining cytosol, are accomplished [11]. The 
following fusion with lysosomes containing proteolytic enzymes, i.e., the formation 
of autophagolysosomes, allows final degradation and reprocessing of their content 
[12]. The formation of the autophagosome is initiated by the phagopore assembly site 
(PAS) where autophagy-related (ATG) proteins are then recruited [13]. Particularly, 
the substantial work of the Nobel Prize laureate Ohsumi of ATG proteins in yeast has 
expedited our knowledge about the formation of the autophagosomes [14]. So far, 20 
ATG proteins have been uncovered in mammalians that are activated during forma-
tion, enlargement, and closure of the autophagosome in a specific order. The process 
of autophagy has been categorized into several steps involving the ATG1/ULK kinase 
complex (initiation), the ATG12 conjugation system (nucleation), the ATG8/LC3 
conjugation/deconjugation system (elongation), the phosphatidyl-inositol 3-kinase 
complex (maturation), and the ATG9/ATG9L1 cycling system (degradation). 
Either tumor suppressor proteins or oncogenes resulting in activation or suppres-
sion, respectively, have been determined to control the process of autophagy [15]. 
Consistently, key regulators that participate in the initial phase of autophagosome 
formation are the nutrient-sensing serine/threonine kinase mammalian target of 
rapamycin (mTOR), the unc-51 like autophagy activating kinases (ULK1/ULK2), 
the Beclin-1 (BECN1) lipid kinase complex, and the ubiquitin-like conjugation 
system (Figure 1) [16–19]. As an overall major player, the mTOR multiprotein 
complex (mTORC) functions, comparable to p53, as a sensor for multiple kinds of 
stress signals which are of genotoxic and oxidative nature, particularly represented 
by reactive oxygen species (ROS), and nutrient levels such as energy, amino acids, 
glucose, or growth factors [19, 20]. The integration of these signals by mTOR beside 
autophagy also serves for the regulation of various other cellular functions such 
as translation, cell cycle, microtubule organization, or lipid biogenesis [21]. The 
mTOR complex subsequently inhibits the ATG13-ULK-FIP200 complex, consist-
ing of ATG13, ULK1 (ATG1), and the focal adhesion kinase interacting protein 
of 200 kD (FIP200), which is necessary to initiate phagopore formation [22–24]; 
frequently, nutrient starvation-induced autophagy involves the formation of this 
complex. Further reports however, also noticed mTOR-mediated downregulation 
of the p53 family member p73 entailing the transcriptional activation of ATG5, 
ATG7, and UVRAG genes [25, 26]. Together with the ATG13-ULK-FIP200 complex, 
mTOR binds to the haplo-insufficient tumor suppressor protein Beclin-1 (ATG6) 
that organizes the phagopore formation and subsequently elongation and matura-
tion of the autophagosome in a concerted action with various interacting proteins 
[27, 28]. For this purpose, Beclin-1 forms the Vps34 core complex consisting of 
Vps15 and class III phosphatidylinositol 3-kinase (PIKC3) that enables the genera-
tion of phosphatidylinositol 3-phosphate (PI3P) [28, 29]. Due to death associated 
protein kinase (DAPK)-mediated phosphorylation, Beclin-1 is not only controlling 
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autophagy but found as a general regulator of lysosomes and endosome formation 
during membrane trafficking [30]. Further maturation of autophagosomes involves 
the interaction of the PI3P-binding proteins WIPI 1/2 with ATG12-ATG5-ATG16L 
and LC3-phosphatidylethanolamine (LC3-PE) complexes, both representing 
ubiquitin-like conjugation systems [4, 18, 31]. LC3 (microtubule-associated protein 
1A/1B-light chain 3) and p62/Sequestosome-1 are two markers that are regularly 
employed for documenting autophagic flux as they are involved in the maturation of 
autophagosomes [32]. While LC3-I is processed to LC3-II, the scaffold protein p62 
interacts with LC3 via its LC3-binding motif and seems to have a role in selectively 
guiding ubiquitinated proteins toward the autophagosome via its ubiquitin-binding 
domain [33]; thus, p62 levels decease during the induction of autophagy and have 
been found moreover to regulate protein deacetylation and is associated with 
tumorigenesis [34–36]. Autophagosome-lysosome fusion that requires the trans-
membrane protein LAMP2 and small Rab GTPases, finally permits hydrolase and 
cathepsin-mediated processing of the autophagosome content [37, 38].
2.1 Positive regulation of p53-mediated autophagy
The tumor suppressor protein and transcription factor p53, which represents 
a “guardian” of the cell, has a fundamental role in the regulation of cell integrity 
Figure 1. 
Nuclear p53-mediated transcription-dependent autophagy, apoptosis and cell cycle arrest in response to stress 
conditions. By upregulation of tuberous sclerosis complex 2 (TSC2) or phosphatase and tensin homolog (PTEN; 
not shown), or AMP-activated protein kinase (AMPK) or its activators sestrins (not shown) p53 prevailingly 
attenuates mammalian target of rapamycin (mTOR) and the unc-51 like autophagy activating kinase 1 
(ULK1) complex (consisting of autophagy-related gene 13 (ATG13) and the focal adhesion kinase interacting 
protein of 200 kD (FIP200)) as the autophagic canonical pathway. ULK-1 then interacts with Beclin-1 
(BECN1) to initiate autophagosome formation. A shortcut for activation of autophagy involves damage-
regulated autophagy modulator (DRAM), death associated protein kinase (DAPK), or autophagy-related gene 
5 (ATG5) upregulation by the p53-family members, p63 and p73, or disruption of BCL2-family-or alternate 
reading frame protein product of the CDKN2A locus (p14ARF)-mediated release of BECN1 inhibition. 
In addition to autophagy, DRAM and p63/p73 are able to activate apoptosis. Arrowlines, upregulation or 
activation by indicated proteins; double arrow, major pathway activity. p53-mediated upregulation of the 
cyclin-dependent kinase inhibitor 1 (p21) enforces cell-cycle arrest. This figure is used under the terms and 
conditions of the creative commons attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) 
derived from Mrakovcic and Fröhlich [57].
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and homeostasis and consequently in tumor defense. It coordinates cellular 
responses such as cell cycle arrest, apoptosis, senescence, metabolism, differentia-
tion, angiogenesis, and even modulates autophagy. Among a multitude of other 
post-translational modifications, acetylation assists the master regulator to sense 
and integrate a variety of endogenous and exogenous cellular stress signals such 
as DNA damage, epigenetic alterations due to DNA methylation, genotoxicity, 
hypoxia, oxidative stress, or oncogene activation [39, 40]. In response, p53, as a 
central transcription factor translocates to the nucleus by detaching from the E3 
ubiquitin ligase, mouse double minute 2 homolog (MDM2), and modulates the 
expression of multiple downstream target genes that regulate processes such as cell 
cycle progression and cell death [41, 42]. In appropriate conditions, p53 induces 
apoptosis by transactivating, i.e., transcriptional activation of pro-apoptotic genes 
or in the cytoplasm by direct interaction with anti-apoptotic proteins located in the 
mitochondrial membrane [43].
Several signaling pathways involving the transactivational activity of p53—in 
normal as well as cancer cells regulate autophagy in the classical canonical mTOR 
pathway as specified in the previous chapter (Figure 1) [44]. As pro-autophagic 
factors emanating from p53, these pathways involve on the one hand the tumor 
suppressor proteins tuberous sclerosis complex 2 (TSC2) and phosphatase and 
tensin homolog (PTEN), and on the other hand the nutrient energy sensor AMP-
activated protein kinase (AMPK) or its activators sestrins 1 and 2 [45–47]. A 
further path that bypasses mTOR and can directly modulate p53 stress-activated 
signal transduction, is damage-regulated autophagy modulator (DRAM) that can 
activate the autophagic as well as apoptotic program [48]. As a protein located in 
the lysosome, it can intervene at different steps of autophagosome formation [49]. 
Furthermore, by either upregulating pro-apoptotic protein expression (BAX, BAD, 
BNIP3, or PUMA) or downregulating anti-apoptotic protein expression (BCL-2, 
BCL-xL and MCL-1) of the B-cell Lymphoma-2 (BCL-2) family, p53 can enforce 
dual activation of autophagy and apoptosis [50, 51]. In the inactivated state these 
proteins directly interact with the BH3 domain of BECLIN-1 and block the direct 
activation of BECLIN-1-dependent autophagy [52, 53]. Direct interaction of the 
nuclear full-length form of p53-modulated tumor suppressor protein p14ARF (an 
alternate reading frame protein of the CDKN2A locus) with the BCL-xL protein is 
a further similar mechanism promoting the induction of autophagy although the 
predominant role of p14ARF seems to stabilize p53 to protect the cell against hyper-
proliferative growth and associated activation of oncogenes [54, 55]. Additionally, 
p53-elicited upregulation of DAPK has been reported to result in autophagic activa-
tion either by DAPK-mediated phosphorylation of Beclin-1 that blocks its degra-
dation by BCL-2/BCL-xL, or by impeding the anti-autophagic LC3-interacting 
MAP1B protein [30, 56].
2.2 Negative regulation of p53-mediated autophagy
Beyond the nuclear-based transactivating pro-autophagic effects mediated by 
p53, additional inhibitory anti-autophagic responses related to cytoplasm-localized 
p53 protein have been uncovered by Tasdemir et al. in the past 10 years (Figure 2) 
[58]. While the transactivation-dependent nuclear autophagic response of p53 
is stimulated by stress induction, the cytoplasmic blockage of autophagic induc-
tion is a steady-state function that is present under physiological conditions and 
seems to engage direct protein interaction. This cytoplasm-mediated inhibition 
of autophagy was also characterized to activate the canonical p53-AMPK-mTOR 
signaling cascade. In contrast to transcription-dependent pathway, however, the 
positive autophagic regulator AMP-dependent kinase is inhibited by p53 which 
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in turn activates mTOR [59]. Accordingly, either pharmacological interference, 
depletion of basal p53 levels, or p53 variants that possess a genetically modified 
nuclear export domain rendered cells more resistant toward metabolic stress 
through elevated autophagy. The underlying obscure mechanism that is found 
not only in mammalians but also in nematodes could involve direct binding of 
p53 to FIP200 (ATG17) as experimentally evidenced [60]. Negative regulation of 
autophagy by cytoplasmic p53 has been also linked to its target gene TIGAR (TP53-
induced glycolysis and apoptosis regulator) that suppresses glycolysis and ROS 
generation when the cell is exerted to stress [61]. Nevertheless, although TIGAR 
mediates ROS-mediated induction of autophagy, it is not a likely candidate for the 
above described mechanism but rather represents an alternative path since it does 
not inhibit mTOR obviously. A similar but also unclear anti-autophagic mecha-
nism could be verified in embryonal carcinoma cells, where p53-Beclin-1 interac-
tion facilitated Beclin-1 ubiquitination and subsequent degradation, which could 
be de-activated by depletion of p53 [62]. Another report identified Beclin-1 as a 
regulator of de-ubiquitination of p53 which was mediated by USP10 and USP13 
ubiquitin-specific peptidases [63]. This mechanism might therefore also relate to 
the previously mentioned Beclin-1-induced autophagy which enables bidirectional 
dual activation of apoptosis and autophagy [64].
2.3 Regulation of autophagy in p53-inactivated cells
p53 is one of the most frequently inactivated tumor suppressor genes in human 
tumors [65]. Particularly, single point mutations that provoke a loss of p53 function 
Figure 2. 
Cytoplasmic p53-mediated transcription-independent autophagy (under physiological conditions) and 
apoptosis. By direct inhibition, wildtype p53-protein inactivates AMPK-mTOR-ULK1 transduced autophagy 
leading to BECN1 degradation. Similarly, BECN1 degradation can also be directly mediated by the ubiquitin-
specific peptidases USP10 and USP13. Further inhibitory functions for autophagy can be mediated by 
TP53-induced glycolysis and apoptosis regulator (TIGAR) following the down-regulation of glycolysis and 
the suppression of reactive oxygen species (ROS) formation. Also, p63/p73 has been reported to presumably 
exert transcription-independent disruption of autophagy (dashed line); fork symbols, inhibition; arrowlines, 
activation by indicated proteins; downward arrow, downregulation. For abbreviations, see Figure 1. This 
figure is used under the terms and conditions of the creative commons attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/) derived from Mrakovcic and Fröhlich [57].
Genes and Cancer
6
were documented that in several cases apply a dominant-negative effect to the 
remaining non-mutant allele thereby enhancing their oncogenic effect [41, 66, 
67]. Often, such p53 variants result in increased genomic instability, attenuated 
chemotherapeutic success and a poor prognosis for patients [68]. One of the 
underlying reasons therefore could be that many tumor-derived p53 variants also 
inactivate cytoprotective or cytotoxic autophagy [69–71]. Nevertheless, although 
nucleus-based transcription-dependent autophagy might be shut down in these 
cases, cytoplasm-induced activation of the autophagic program might still be 
available, due to p53-deficiency or functional inactivation. Interestingly, the studies 
of Morselli et al. demonstrated that several tumor-derived mutants of p53 that 
reside in the cytoplasm are still able to block autophagic induction, presumably by 
direct protein interaction [70]. Such experiments underline the significance why 
it is meaningful to discriminate p53 mutant variants with regard to their potential 
effects. This finding also highlights the role of context-dependent autophagy during 
tumorigenesis as disabled autophagy by mutant p53 was found to prolong tumor 
cell survival while it inactivated its tumor suppressor function. Thus, increased 
proliferation of pancreas and breast cancer cells could be uncovered in a report that 
confirmed inhibition of autophagy by mutant gain-of-function p53 proteins. This 
counteractivity was evidenced by stimulation of AMPK-mTOR genes with con-
comitant downregulation of Beclin-1, DRAM, ATG12, and sestrin genes [72].
Various investigations found also a counter-acting surveillance mechanism 
between autophagy and since as mutant p53 blocks autophagic induction in one 
way but autophagy can stimulate the sequestering of mutant p53 in order to sup-
press tumorigenesis in the other way. Mechanistically, this mutual crosstalk is 
translated by the regulatory actions of the two suppressor genes Beclin-1 and p53 
on autophagy as specified in the previous chapter [63]. While p53 exerts control on 
Beclin-1 via the canonical autophagic pathway, Beclin-1 also directly regulates p53 
via controlling its deubiquitination activity which explains the mirrored effect on 
the phenotype of p53- and Beclin-1 ablated mice [73]. Additionally, with respect 
to Beclin-1 mediated autophagy, further reports documented the possibility of 
autophagic activation via the tumor suppressor protein p14ARF in p53-silenced 
or -inhibited cells [74]. Studies using doxorubicin-treated p53-wildtype or -deficient 
(p53−/−) mouse embryonic fibroblasts furthermore verified that the p53 family 
members p63 and p73 can substitute the loss of p53 (Figure 2) [75]; this mecha-
nism involved nucleus translocation of p63/p73 and the increased expression of an 
extensive network of ATG proteins, such as ATG4a, ATG4c, ULK1, ULK2, UVRAG, 
and ATG5. This finding might explain resistance in doxorubicin-mediated chemo-
therapeutic treatment of cancer tissues.
3. Histone deacetylases and histone deacetylase inhibitors
Histone acetylation by the families of histone acetylases (HATs) histone 
deacetylases (HDACs) are crucial epigenetic elements in the regulation of gene 
transcription of histone as well as non-histone proteins. HATs catalyze acetyla-
tion to lysine residues of proteins, which stimulates a relaxed transcriptionally 
accessible chromatin configuration, while HDACs facilitate their removal associ-
ated with a closed transcriptionally inaccessible chromatin structure [76, 77]. 
Acetylation of histones and non-histones not only interferes with gene expression 
but crucially governs cell signaling and cellular processes such as proliferation, 
differentiation, and programmed cell death [78]. Identified non-histone substrates 
to date are tumor suppressor proteins (e.g., p53, RUNX3), signaling mediators 
(e.g., STAT3, β-catenin, Smad7), steroid receptors (e.g., androgen, estrogen, SHP), 
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transcriptional factors, and co-regulators (e.g., c-Myc, HMG, YY1, EKLF, E2F1, 
GATA factors, HIF-1α, MyoD, NF-κB, and FoxB3), as well as structural  
(e.g., cell motility proteins), chaperone proteins, and nuclear import proteins (e.g., 
α-tubulin, importin-α, Ku70, HSP90) [79].
Depending on function or structure, four classes (class I–IV) have been allocated 
that comprise 18 members of the HDAC family [80]. The “classical HDACs” contain 
classes I and II and are functionally dependent on zinc as co-factor, while class III 
HDACs include the sirtuin proteins (Sirt1-7; homology to yeast Sir2) and require 
NAD+ [81]. Nevertheless, HDACs also differ in subcellular localization, and expres-
sion pattern [78]. While class I HDACs are expressed ubiquitously as they are located 
in the cell nucleus providing them with superior enzymatic activity, class II HDACs 
possess restricted tissue-specific expression pattern. Thus, they have been sub-
divided into class IIa HDACs (HDAC4, 5, 7 and 9) which shuttle between nucleus 
and cytoplasm as well as class IIb HDACs (HDAC 6 and 10) that are located mostly in 
the cytoplasm [82]. SIRTs exhibit specific subcellular presence in the nucleus (Sirt1, 
6 and 7), in the cytoplasm (Sirt2), or in mitochondria (Sirt3, 4 and 5) which is not 
interchangeable. HDAC11, the single less-well explored member of class IV HDACs, 
has narrowed tissue expression [83].
HDAC inhibitors (HDACi) have been explored as a new category of anticancer 
drugs that reverses epigenetic changes established by the deregulated activities of 
HDACs in hematological as well as solid cancers [84]. HDACi treatment induces 
transcriptional de-repression of genes that are eminent regulators of tumor cell 
activities such as cell cycle arrest, differentiation, and programmed cell death and 
even the expression and stability of oncoproteins [85]. HDACi categories encompass 
hydroxamic acids (hydroxamates), cyclic tetrapeptides, benzamides, electrophilic 
ketones, and aliphatic acids that include natural but also synthetic derivatives that 
exhibit different structures [84]. Favored representatives of the hydroxamates 
are SAHA (suberoylanilide hydroxamic acid, vorinostat, and Zolinza) which is 
a preferred derivative of naturally occurring trichostatin A (TSA) as well as the 
CBHA (m-carboxycinnamic acid bishydroxamate)-derived tubacin, LAQ-824 
(dacinostat), LBH-589 (panobinostat), or PXD-101 (belinostat) [86–89]. The class 
I-selective FK-228 (romidepsin, FR901228, istodax) belongs to the group of cyclic 
tetrapeptides [90]. MS-275 (entinostat) and MGCD0103 (mocetinostat) exhibiting 
enhanced HDAC class I selectivity are members of benzamide-based HDACi [91, 
92]. The minor effective class I- and IIa-specific HDACi, VPA (valproic acid), PBA 
(phenylbutyrate), NaB (sodium butyrate), or AN-9 (pivaloyloxymethyl butyrate) 
belong to the category of aliphatic acids [93, 94]. This classification mainly depends 
on the chemical structure of their zinc-binding group but in addition HDACi can 
also be subdivided into zinc-dependent, pan- or broad-spectrum inhibitors that 
inhibit all class I, II and IV HDACs in contrast to primarily class I-specific HDACi 
[95]. Representatives of pan-inhibitors are TSA, SAHA, LBH589, and PXD-101 
while valproic acid and butyrate inhibit exclusively class I HDACs. MS-275 and dep-
sipeptide inhibits only a few members of class I HDACs, respectively. To date, the 
HDAC6-specific inhibitor tubacin is the only representative of an isoform-specific 
HDACi [86]. With the exception of nicotinamide, no clinical useful SIRT inhibitors 
have been uncovered yet [96].
Clinical trials of single or combined treatments of several HDACi with diverse 
results have been or are in the progress of being tested in hematological and solid 
cancers (www.clinicaltrials.gov) [97, 98]. Up to now, exclusively the evaluation of 
pan-inhibitors have succeeded in the admittance of four licensed HDACi, namely, 
SAHA, panobinostat (LBH589), belinostat (PXD-101), and romidepsin (FK228) 
for the treatment of cutaneous T cell lymphoma, multiple myeloma, or peripheral 
T cell lymphoma, respectively [99–103]. Although preclinical studies using single 
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treatment regimen of many HDACi were encouraging, almost all entities of solid 
tumors (e.g., ovarian, breast, renal, prostate, and head and neck cancer) lacked 
positive effects in phase II clinical trials [104, 105]. In addition, patients suffered 
from trivial (e.g., dehydration, anorexia, diarrhea) to toxic (e.g., cardiotoxicity, 
thrombocytopenia myelosuppression) non-selective side effects [85, 94, 106]. 
The reasons for these drawbacks are presently non-elucidated and were assumed 
to be due to a combination of failing blood vessel supply, endogenous molecular 
heterogeneity owing to epigenetic modifications, and the development of treatment 
resistance. In response, selective HDAC-specific inhibitors are being developed, 
that target only one or two isozymes [107]. The design of novel or improved specific 
inhibitors will allow the full exploration of individual functions of distinct HDAC 
activity and may furthermore provide improved therapeutic efficacy together with 
less toxicity.
4. Mechanisms of histone deacetylase inhibitor-induced cell death
Owing to the various posttranslational histone and non-histone protein acetyla-
tion targets, HDACi exert a multitude of anti-tumor effects that concern interference 
with growth, differentiation, migration, senescence, and death [108]. Although 
there may be tumor cell-type and HDACi-specific effects which are unclear pres-
ently, common mechanisms are shaping for different HDACi [85, 108]. Induction 
of apoptosis is by far the prevailing avenue of HDACi triggered cell death in trans-
formed cells which is prepared by re-induction of cell cycle arrest and induction 
cell differentiation, e.g., by the downregulation of positive cell growth regulators 
[109–112]. G1 or G2 phase induced cell cycle arrest in the G1 or G2 phase can occur 
in a p53-dependent or -independent manner by stimulating the upregulation of 
(p21waf-1/cip1) expression which is a cyclin-dependent kinase (CDKN) inhibitor of 
cyclins D1/D2 [113–115]. As an underlying mechanism it is assumed that the inability 
to exit the cell cycle from unfinished mitosis might sensitize the activation of apop-
tosis due to compiled DNA damage such as double-strand breaks [116, 117]. HDACi-
stimulated activation of the intrinsic (mitochondrial) pathway of apoptosis involves 
either down-regulation of anti-apoptotic genes (e.g., BCL-2, BCL-XL, XIAP, MCL-1, 
and survivin) or overexpression of pro-apoptotic genes (e.g., BAX, BAK) belong-
ing to the B-cell Lymphoma-2 (BCL-2) family [113, 114, 118, 119]. In the extrinsic 
(death-receptor) pathway, HDACi predominantly re-establish the expression of 
death receptors such as DR4 and DR5, or their corresponding ligands (e.g., TRAIL, 
FAS, FAS-L, and TNF-alpha) [120–122]. Furthermore, also the induction of reactive 
oxygen species (ROS) by HDACi is a second important anticancer-mechanism that is 
also responsible for cell death induction and associated with DNA damage; presum-
ably, ROS is scavenged in normal, but not in malignant cells due to the compiled 
expression of thioredoxin (TXN) which represents an endogenous cellular antioxi-
dant [123]. HDACs have moreover been detected to control histone deacetylation at 
damaged DNA sites undergoing repair that involves DNA damage-related response 
proteins [95, 124–132]. Thus, only in tumor cells upregulated expression of a marker 
for DNA double strand breaks, H2AX, was detected, when these were treated with 
SAHA [117]. In this context also the induction of autophagy as a means to maintain 
genomic was noticed, for instance, following MSH2-regulated DNA mismatch repair 
deregulation upon HDAC6 inhibition. Cell signaling pathways that were shut down 
in cancer cells can be furthermore re-established by immediately modifying acetyla-
tion of non-histone proteins such as transcription factors (e.g., NF-κB, p53, and 
STATs) [79]. As a prominent example, half-life and stability of p53 was influenced 
by MDM2 E3-ligase in HDACi-treated H1299 carcinoma cells [42]. In this way also 
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chaperone protein function and the regulation of stress response pathways in the 
endoplasmic reticulum can be achieved, which affects the removal of misfolded pro-
teins but also interference with stability and expression of oncoproteins [111, 133]. 
Additional mechanisms of HDACi-regulated lethality in tumor cells were evidenced 
in the interference with migration- and invasion capability due to re-established 
expression of metastasis-related genes and in the disruption of angiogenesis by alter-
ing pro- and anti-angiogenic gene expression [134–136]. In recent years, autophagy 
as a form of programmed cell death was added to the list of further determinants 
of HDACi-mediated effects that impedes cellular growth in a range of tumor cells 
[137–140].
5. Mechanisms of HDACi-induced autophagic cell death
An impressive diversity of mechanisms have been uncovered in cancer cells that 
promote HDACi-elicited autophagy which include mostly attenuation of mTOR sig-
naling that can occur in combination combined with increased expression of LC3, 
Beclin-1, or ATG and can be provoked by endoplasmic reticulum stress (reviewed in 
[57] and Table 1 [141]). mTOR is a well-known regulator of the canonical pathway 
of autophagy involving the regulation of the ULK1 complex and Beclin-1. The 
pivotal role of mTOR attenuated by SAHA-treatment which reestablishes ULK1 
function could be initially verified by our own studies and those of Gammoh et al. 
using endometrial sarcoma cells, and were subsequently reiterated in many studies 
[71, 142]. It should be noticed that HDACi-induced autophagy is frequently accom-
panied by the additional induction of apoptosis.
Further predominant mechanisms of autophagic induction involve ROS 
accumulation, p21 upregulation, NF-κB hyperacetylation, and sirtuin-mediated 
acetylation of p53 [143–146]. In addition to mTOR downregulation, substantial 
intracellular ROS production interfering with mitochondrial function and energy 
metabolism has been demonstrated to facilitate SAHA-induced autophagy in tumor 
cells. ROS-induced autophagy can go along with additional increased expression of 
cathepsin D, a lysosomal protease, or decreased expression of TRX, representing 
its substrate and/or activation of the mitogen activated protein kinases ERK1/2 and 
JNK [143, 147]. Generally, enzymes related to energy metabolism, anti-oxidative 
stress and cellular redox control have been entangled by a proteomic study involv-
ing SAHA-administered Jurkat T-leukemia cells [147]. Cell cycle arrest, differentia-
tion, and autophagy due to upregulated p21 expression were caused by treatment of 
PC-3 M and HL-60 cells with HDACi SAHA and H40 [148]. The same mechanism 
could be elicited by adding the novel HDACi, MRJF4, to prostate cancer cells 
autophagy [144]. As a further cause of SAHA/MS-275-induced autophagy in PC3 
prostate cancer cells, re-activation of NF-κB associated target genes due to hyper-
acetylation of NF-κB RELA/p65, or downsizing of pERK/NF-κB signaling together 
with upregulated p21 expression, were described; however, the exact mechanism 
remains obscure [146].
Individual studies also noted nuclear translocation of the apoptosis inducing 
factor (AIF), apoptosome inactivation, FoxO1-stimulated expression, upregulation 
of DAPK or Nrf2, and p53-deficiency as regulatory mechanisms in HDACi-induced 
autophagy [71, 146, 149–153]. Thus, apoptosis, necrosis or autophagy were trig-
gered in malignant rhabdoid tumor cells in response to FK228 (depsipeptide) treat-
ment and upon silencing of the apoptosis inducing factor (AIF) that translocates 
into the nucleus for caspase-induced death, autophagy was suppressed as supported 
by transmission electron microscopy and LC3 measurements [149]. Following the 
blockage of the mitochondrial pathway of apoptosis by deleting caspase-9 or Apaf-1 
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Molecular 
mechanism
Additional mechanism HDACi Cell type Ref.
mTOR 
inhibition
Increased p21 expression SAHA ESS-1 [156]
Increase of LC3 expression; 
activation of ULK-1 
complex
SAHA MEFs, T98G 
glioblastoma
[142]
Beclin-1 upregulation SAHA, 
butyrate
HelaS3 [157]
Induction of ER stress 
response
SAHA, 
OSU-HDAC42
HCC, Hep3B, HepG2 [158]
ROS accumulation via 
Cat D, repression of 
TRX; BECN1 and ATG-7 
upregulation.
SAHA Jurkat T-leukemia [147]
BECN1 protein 
upregulation. and p62 
downregulation
SAHA Glioblastoma stem 
cells
[159]
CASP and CPN-1 
activation; reduced ATG 
expression*
MGCD0103 Primary CLL [160]
Increased ATG5 expression Apicidin Salivary MEC [161]
ROS 
accumulation
CathD upregulation and 
TRX repression
SAHA K562, LAMA 84 
CMLL
[143]
Activation of MAPK 
proteins: ERK1/2 and 
JNK; LC3 and ATG12 
upregulation
FK228+
bortezomib
Gastric carcinoma 
(GC)
[162]
p38 MAPK switch to 
apoptosis; ERK activation
M-275 HCT116 [163]
p21 CIP/WAF1 
upregulation
– SAHA, H40 PC-3 M, HL-60 [148]
Downregulation of pERK/
NF-κB signaling
MRJF4 PC3 [144]
NF-κB Hyper-
acetylation
Induction of NF-κB target 
genes
SAHA, MS-275 PC3 [146]
AIF nucleus 
translocation
– FK228 MRT [149]
Apoptosome 
inactivation
Independent of p53; 
Deletion of Apaf-1/Casp-9
LAQ824, 
LBH589
Eμ-myc lymphomas [152]
FoxO1 
transcription
ATG expression; mTOR 
suppression via SESN3
SAHA, TSA HepG2, HCT116 [150]
DAPK 
upregulation
– LBH589 HCT116 [151]
Nrf2 
upregulation
mTOR suppression via 
miR-129-3p
– – [153]
ATG7 
acetylation*
Autophagy interactome 
acetylation; increased 
mitochondrial mass and 
ROS formation
SAHA, TSA, 
LBH589, JQ2
Megakaryoblastic 
leukemia
[154]
ATG gene 
upregulation*
Independent of p53 
acetylation
Tenovin-6 CLL [155]
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or in Eμ-lymphomas the autophagic pathway was activated by the HDACi LAQ824 
and LBH589 as evidenced morphologically and biochemically [152]. SAHA and 
TSA-induced autophagic cell survival via the transcription factor FoxO1 in HepG2 
and HCT116 cells was furthermore mediated by sestrin 3 (SESN3)-induced mTOR 
inhibition and increased ATG protein expression [150]. Protein interaction or 
phosphorylation of the MAPK-interacting calcium- or calmodulin-regulated DAPK 
at serine 308 in HCT116 colon cancer cells, rather than its enzymatic function, 
moreover stimulated LBH589-induced autophagy [151]. Recently, even microRNA-
mediated regulation of mTOR involving the transcription factor Nrf2 (nuclear 
factor erythroid 2 like-2) was implicated in HDACi-induced autophagy [153]. 
HDACi-induced Nrf2 mRNA and protein expression thereby promoted augmented 
transcription of miR-129-3p which facilitated mTOR attenuation. Nonetheless, 
even HDACi-mediated suppression of autophagy could be documented in two 
studies. Negative regulation of HDACi-mediated autophagy but upregulation of 
autophagic flux could be induced in myeloid-leukemic cells treated with valproic 
acid, SAHA, TSA, panobinostat, or JQ2 by acetylation and decreased expression 
of ATG7, a protein important for fusion of peroxisomal and vacuolar membranes 
[154]. Additionally, increased ATG expression following treatment with sirtuin 
inhibitor tenovin-6 provoked autophagic suppression in chronic lymphocytic 
leukemia (CLL) cells which was evident by upregulated genes of the autophagic-
lysosomal pathway and LC3-II/p62 [154, 155].
6. HDACi-induced autophagy mediated by p53
p53 as the first described representative subjected non-histone protein acetyla-
tion can in response to stress positively as well as negatively regulate cell cycle 
arrest, senescence as well as apoptosis and autophagy [39, 40]. Acetylated residues 
attached by distinct HAT-mediated acetylation can be detected for p53 at distinct 
sites that could not only affect DNA binding and thereby its transactivational 
ability but also coactivator recruitment and/or its stability via proteasomal deg-
radation [166–168]. For example, HDAC1-specific inhibition allows p53 to stay in 
an accessible state associated with transcriptional activity [169]. Furthermore, by 
mutating a combination of C-terminal sites that undergo acetylation p53-dependent 
transcription of p21 can be eliminated [170]. Nevertheless, the exact modalities of 
these mechanisms still need clarification. As previously specified, HDACi-mediated 
Molecular 
mechanism
Additional mechanism HDACi Cell type Ref.
p53 
acetylation
Increased p53-dependent 
cell cycle arrest and 
apoptosis
Sirtinol MCF-7 [145]
p53 activation. by reducing 
MDM2 expression; cell 
cycle arrest and apodosis
MHY2256 MCF-7 [164]
p53-deficiency mTOR inhibition SAHA ESS-1 [165]
*Leads to inhibition of autophagy; AVO (acidic vesicular organelles); (−), unknown or not determined. This 
modified Table is used under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/) from Mrakovcic et al. [141].
Table 1. 
Mechanisms of HDACi-induced autophagic cell death.
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apoptosis that is commonly escorted by p21-mediated cell cycle arrest and ROS 
generation, has been documented as the most frequently encountered form of 
HDACi-triggered cell death [112, 119]. However, since transcription of pro-
apoptotic genes, such as Bax, Noxa, and Puma, by p53 may be limited by posttrans-
lational acetylation, the role of p53 in this relation is discussed. These assumptions 
are supported for example by the finding that p53-independent p21 induction and 
apoptosis upon HDACi administration and the anticancer effect of HDACi is not 
influenced by the mutational status of p53 in the tumor [109, 113]. Other reports 
in contrast verified p53 acetylation and stabilization in several tumor models in 
response to HDACi administration that presented cell cycle arrest and apoptosis 
[111, 171]. Conclusively, p53-dependent but also -independent signaling pathways 
may add to HDACi-mediated apoptotic processes and HDACi may induce p53, but 
do not unconditionally require p53 for providing anticancer effects. In recent time, 
the range of HDACi-exerted mechanisms resulting in cellular demise of cancer cells 
have been expanded by the induction of autophagic cell death which can alterna-
tively or additionally to apoptosis activate autophagy (reviewed in [57, 141, 172] and 
Table 1). Also, involvement of posttranslational modification of the non-histone 
p53 has been linked to the control of HDACi-stimulated autophagy as evident from 
its key regulatory role in normal cells. This might of crucial advantage if tumor cells 
have developed resistance toward apoptotic cell death induction. Thus, experimen-
tal evidence from our studies of endometrial sarcoma (ESS) cells support a major 
regulatory function for p53 in directing cell death either toward HDACi-elicited 
apoptosis or autophagy [165].
In our model, the detection of HDAC2 overexpression in malignant endo-
metrial stroma sarcoma cell lines led to the establishment of therapeutic SAHA 
treatment and the evaluation of its mechanism of action [173]. Significantly 
advanced cell death in MES-SA and ESS-1 cells was accompanied by previous p21-
induced cell cycle arrest at the G1/S transition and reduced expression of HDAC2 
and 7 [156, 173]. Either predominant caspase-dependent apoptotic (48%) or 
caspase-independent autophagic cell death (80%) was attested in SAHA-treated 
MES-SA and ESS cells after 24 h, respectively [156]. In line with the induction of 
the canonical pathway of autophagy, attenuated mTOR protein expression could 
be evidenced in ESS-1 cells in contrast to MES-SA cells [165]. Further screening 
of key regulatory molecules for apoptosis and for autophagy, upstream of mTOR, 
were performed to explain the differences in the modes of SAHA-induced cell 
death. This search uncovered entire absence of detectable p53 protein and lowered 
levels of PUMA protein in ESS-1 cells. Investigation of p53 gene and mRNA led 
to the detection of a novel nonsense mutation (p53R213X) in the transactivating 
domain of p53 of ESS-1 cells that obviously provoked a degradation of the entire 
p53 transcript and could not be documented in MES-SA cells. Consistent with this 
finding, restoration of ESS-1 cells with a wild-type p53 variant restored induction 
of caspase-dependent apoptosis as supported by PUMA and caspase-9 upregula-
tion as well as activation of the effector caspases-3 and -7 and final PARP-1 cleav-
age. Increased mTOR levels demonstrated the re-induction of basal autophagic 
flux in addition to apoptosis induction as verified by LC3 staining. Generalization 
of this finding could be obtained by several other p53-deficient tumor cell lines 
(such as PANC-1, Jurkat, HL-60, and U937) that are known to induce autophagy 
in response to SAHA and were supplied with wild-type p53.
We concluded that the molecular switch between SAHA-induced apoptosis 
and autophagy was thus mediated by the occurrence of functional p53 protein. 
Our experimental evidence thus underlines an overall major regulatory role 
for p53 not only in HDACi-mediated apoptosis but also in HDACi-stimulated 
autophagy (Figure 3) (reviewed in [57, 141]). As a consequence, p53-deficiency 
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could moreover explain apoptosis resistance as well predominant induction of 
HDACi-provoked autophagy in cancer cells. The presumptive negative regulation 
of autophagy by functional cytoplasmic p53 protein in SAHA-treated ESS-1 cells is 
Figure 3. 
Illustration depicting presumed mechanisms mediating SAHA-induced autophagy reflecting autophagic 
regulation by cytoplasmic mutant and wild-type p53. (A) Acetylated cytoplasmic p53 protein predominantly 
activates apoptotic cell death by direct binding to the BCL-2 family of pro-apoptotic proteins. Concomitantly, 
cytoplasmic p53 protein inhibits autophagic cell death by inducing Beclin-1 degradation via USP10/USP13 
and/or inhibiting the AMPK-mTOR-ULK1 signaling pathway. It is unclear whether the canonical pathway 
is mediated by direct p53-FIP200 interaction or whether this represents an extra pathway. TIGAR inhibits 
autophagy by down-regulation of glycolysis and a suppression of ROS formation. The members of the p53 
family, p63/p73, are also potential inhibitors of autophagy (dashed line). (B) Mutant p53 protein variants 
lose the ability of autophagic inhibition and apoptosis stimulation and activate autophagy. Fork symbols, 
inhibition; arrowlines, activation or interaction; double arrow, major pathway activity. This figure is used 
under the terms and conditions of the creative commons attribution (CC BY) license (http://creativecommons.
org/licenses/by/4.0/) derived from Mrakovcic and Fröhlich [57].
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moreover very consistent with the above discussed role of p53 as a dual regulator 
of autophagy by Tasdemir et al. [59]. Their findings convincingly describe nuclear 
p53 protein as an activator of transcription-dependent autophagy, in contrast to the 
inhibitory autophagic control by cytoplasmic p53 protein. In addition, by our report 
we link SAHA-induced acetylation of p53 to the mTOR signaling pathway which has 
been less evaluated to date, nonetheless, future experiments are needed to directly 
address this question.
In line with our experiments, the class III Sirt1 and 2-specific HDACi sirtinol, 
that affects acetylation of p53, has also been documented to determine HDACi-
induced cell fate in several reports. For instance, p53 was entangled in balancing 
sirtinol-mediated apoptosis and autophagy in MCF-7 breast cancer cells [145]. 
Sirtinol treatment on the one hand preferentially induced predominant autophagy 
as shown by LC3-II upregulation, while addition of the autophagic inhibitor 
3-methyladenine augmented cell cycle arrest and cytochrome C-triggered apoptotic 
cell death caused by increased BAX and diminished BCL-2 protein expression. In 
a similar experiment, inhibition by sirtinol and the novel SIRT1, -2, and -3 protein 
inhibitor, MHY2256, a similar phenotype that included cell cycle arrest and both 
types of programmed cell death could be provoked [164]. As a mechanistic explana-
tion, SIRT1 and 2-induced acetylation of p53 at lysine 382 were found to inhibit 
ubiquitination of p53 via MDM2 which stabilized and increased its functional activ-
ity. MDM2-mediated degradation of p53 was also documented in MHY2256-treated 
Ishikawa cells that are derived from endometrial cancer which elicited activation of 
apoptosis together with autophagy as supported by elevated levels of p21, BAX and 
BCL-2, cytochrome C release, and cleaved PARP-1 [174].
7. Conclusions and perspectives
In recent times, epigenetic studies gained increasing significance in reports 
investigating the development of cancer. For this purpose, aberrant epigenetic 
patterns such as DNA methylation including the misguided expression of HDACs 
activity has been defined to some extent in many tumors which explains their selec-
tion as targets for anticancer therapy. Posttranslational modifications of histones 
and non-histones in the form of acetylation and deacetylation particularly enable 
pharmacological interference by different kind of inhibitors such as HDACi. The 
ability to sensitize apoptosis-resistant tumor cells by the disruption of autophagy 
was considered a promising route for cancer therapy as this process heightens the 
pro-apoptotic effects of HDACi. In addition to restrain the extents of tumor necro-
sis and inflammation however, autophagy might be required for the cancer cell to 
deal with metabolic stress and cytotoxicity during chemotherapy. Furthermore, by 
expediting the autophagic pathway in advanced stages of the cancer cell, autophagy 
may promote cell death by mostly non-elucidated mechanisms. Consistently, it is of 
pivotal importance to define the factors and mechanisms that influence the balance 
between HDACi-elicited apoptosis, autophagy or even necrosis in the cancer cell. In 
this regard, considerable research efforts are in progress to investigate the molecular 
pathways regulating HDACi-mediated cell death in tumor cells. The expansion of 
the knowledge about p53 as a mediator of apoptotic and autophagic cell death may 
as thus help to achieve progress not only in unraveling pathogenetic insights but 
also in the development of novel therapeutic strategies of such disease conditions as 
cancer.
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